ScreenerHero

AMRX Amneal Pharmaceuticals, Inc.

Partial data
NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · amneal.com
20.40USD+1.19%Mkt Cap: 7.02B $P/E: 42.00

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, I…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8
SFZN
Siegfried Holding AG
$3.47BUSDP/E 17.7

Key Statistics

Company
Market Cap7.02B USD
Enterprise Value9.23B USD
Revenue (TTM)3.12B USD
Gross Profit1.11B USD
Net Income (TTM)72.06M USD
Revenue/Share9.87 USD
Last Price20.40 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8.7K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS03168L1052
Valuation
P/E (Trailing)42.00
P/E (Forward)17.02
PEG1.91
EV/EBITDA13.38
EV/Revenue2.96
P/S2.27
P/B197.09
EPS (TTM)0.48
EPS (Forward)1.19
52W Range
9.49093% of range21.17
52W High21.17 USD
52W Low9.490 USD
Profitability
Gross Margin36.88%
Oper. Margin18.34%
EBITDA Margin22.12%
Profit Margin2.39%
ROE-101.78%
ROA1.96%
Growth
Revenue Growth9.90%
Earnings Growth157.10%
Cash Flow & Leverage
Operating CF339.99M USD
CapEx (TTM)114.36M USD
FCF Margin-3.70%
FCF Yield-1.64%
Net Debt2.66B USD
Net Debt/EBITDA3.86
Balance Sheet
Debt/Equity-37.98
Current Ratio2.21
Quick Ratio1.38
Book Value/Sh0.10 USD
Cash/Share0.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)22.71 USD
Upside (mean)+11.3%
Target Range20.00 USD – 27.00 USD
20.00+11.3% to mean27.00
# Analysts7
Ownership
Shares Out.348.30M
Float197.33M
Insiders52.10%
Institutions48.46%
Short Interest
Short Ratio7.2d
Short % Float4.60%
Short % Out.3.24%
Shares Short11.29M
Short (prev mo.)9.51M
Technical
SMA 5018.27 (+11.6%)
SMA 20014.97 (+36.3%)
Beta1.24
S&P 52W Chg14.16%
Avg Vol (30d)2.05M
Avg Vol (10d)3.70M
Technical Indicators
RSI (14)69.8
MACD0.2567
MACD Signal0.0251
MACD Hist.+0.2315
BB Upper19.28 USD
BB Middle17.75 USD
BB Lower16.22 USD
BB Width17.27%
ATR (14)0.7877 USD
Vol Ratio (20d)2.83x